Get started

Chinastocks

Baidu: Deep Pullback to Key Support and a Golden CrossChinese stocks have been surging this year as investors embrace the country’s flourishing digital economy. However, one of its most established names hasn’t broken out yet: Baidu – “the Google of China.” BIDU entered the current environment in a weak place after years of revamping its search and advertising business. However it’s reported strong results in the last four quarters. It also surged in June on a report that Tencent may increase its stake in Iqiyi , which is majority owned by BIDU. BIDU has pulled back and digested a lot of its gains in the last two weeks. It’s returned to the $118-120 area where it’s consolidated and pivoted several times in the last year. The stock also just had a “Golden Cross,” with the 50-day simple moving average (SMA) rising up and through the 200-day SMA. This can reflect a long-term change in momentum – potentially interesting in a stock that’s lost more than half its value since July 2018.
NASDAQ:BIDULong
by TradeStation
Moderna in Trouble - ABUS Wins Lawsuit Tied to COVID-19 DrugArbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. AFTER HOURS BREAKING NEWS Moderna stock tumbled late Thursday after the biotech lost a patent battle that may jeopardize the financial future of its coronavirus vaccine. Moderna (MRNA) challenged patents held by Arbutus Biopharma (ABUS) covering lipid nanoparticle, or LNP, technology. Lipid nanoparticles are the delivery system for messenger RNA drugs, including Moderna's coronavirus vaccine, which is known as mRNA-1273. Despite the company's contention, the ruling could cut into profits on any Moderna drug, including mRNA-1273, says SVB Leerink analyst Mani Foroohar. "Revenue concentration in (the coronavirus vaccine) is a central feature of the investment case for Moderna shares," Foroohar said. "Any meaningful royalty burden could hamper Moderna's pricing flexibility and margin profile vs. other players in the SARS-CoV-2 vaccine market." Foroohar called the decision in Arbutus' favor "a disappointing turn for Moderna." "This decision opens the door to a fascinating (and likely protracted) period of investor controversy and debate around the implications of any potential infringement of claims by Arbutus regarding Moderna's use of Lipid Nanoparticle delivery technology, and any further actions Moderna may take to defend their own (intellectual property) position and freedom to operate," he said. NEWS: www.investors.com Where's ABUS going? To $100.00 ...??? On the monthly chart, it looks like $9.00 might be the next stop..? At this point, I am not sure if there is a top right now for ABUS. The news is huge for ABUS and could entitle ABUS to billions in profits and revenue from the COVID-19 vaccine. Intelligent comments welcome. DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:ABUSLong
by HotCharts
4
Timeline: NIO vs. TSLA = NIO Target $350 to $500Don't shoot the messenger! I have a timeline of Tesla below which should put a price target on NIO North of $400 to $500 a share. www.thestreet.com As we stand today, NIO is much more successful than Tesla ever was and at this time, or there a bouts, compared to Tesla at or around the same time period in production & sales, Tesla was trading north of $360 a share and only delivered 2,400 cars compared to NIO delivering over 46,000 vehicles. "Entering 2018 Tesla faced several difficulties. Missed predictions had led investors to dump the company's stock, and in the middle of 2017 it lost more than 5% of its value in a collapse worth $12 billion. By January, 2018 Tesla was producing its Model 3 sedans at a fraction of the rate it had anticipated. Over a three-month period the company managed to finish and ship 2,400 cars after promising consumers and investors that it could complete more than 5,000 per week." On 07/02/2020, NIO announced as of June 30, NIO delivered 46,082 vehicles with 14,169 already delivered for 2020. These sales figures topple what Tesla sold and at or around the same time period, Tesla stock spiked to around $389.61. These are real figures from the Tesla timeline I have listed herein and using monthly stock charts for Tesla's stock price at that time period. NIO is also in much better financial condition than Tesla ever was at or around the same time in the production and sales cycle / timeline. Folks, when you look at the monthly stock prices for Tesla, and compare the timeline link I have herein, NIO is extremely cheap and deeply undervalued at current levels. Also, NIO has the Chinese Government behind them. Tesla, at or around when the company started, only raised $500 million from a DOE loan and Tesla was burning cash like water. NIO just raised almost $1 Billion in funding. NIO is financially in a better place than what Tesla ever was. The way I see it, the Chinese Government will not let NIO fail to Tesla, a USA auto company. In my opinion, after researching Tesla vs. NIO, I personally think NIO should be trading at or around $350 to $500 a share with their financial and sales figures. Best of luck longs! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NYSE:NIOLong
by HotCharts
12
JD.com: Pullback in Chinese Momentum StockThis one is short and simple: JD.com just had its first decent pullback since it started running in May. JD has a few things going for it. First, the Beijing-based e-commerce stock spent almost all of June consolidating on either side of $60. It ripped over that level after the Independence Day weekend and has now retraced that surge. Will the old resistance zone around $60 become support? Second, JD has tested and held its 21-day exponential moving average (EMA). The last time it did that was way back on May 6. Third is the relative strength . Money has streamed into Chinese technology stocks because of changes in global indexes and a quicker recovery from coronavirus.
NASDAQ:JDLong
by TradeStation
$CMCM can rise in the next daysContextual immersion trading strategy idea. Cheetah Mobile Inc. operates as a mobile Internet company. The demand for shares of the company still looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $2,71; stop-loss — $2,41. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NYSE:CMCMLong
by KozakHlib
$CPHI can rise in the next daysContextual immersion trading strategy idea. China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The demand for shares of the company still looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $0,69; stop-loss — $0,65. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
AMEX:CPHILong
by KozakHlib
Bullish Charts - In-Home COVID-19 TestCo-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah. Daily Chart MACD, RSI & STOCHASTIC are turning up, Bullish Volume is also picking up steam. On 06/09/2020, CODX announced the company will be added to the Russell 2000 and 3000 Indexes On 05/28/2020, Analysts set price targets at $30 and $36 On 05/26/2020, CODX said its Logix Smart Covid-19 test kit was used to demonstrate that the SARS-CoV-2 virus can be detected in cancer tissue of coronavirus patients. On 05/18/2020, Price Target Raised to $35.00 The stock looks like it's on the verge of breaking out much higher. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:CODXLong
by HotCharts
Bullish Charts - COVID-19 Play, N95 Masks, Robust EarningsAlpha Pro Tech, Ltd., together with its subsidiaries, engages in developing, manufacturing, and marketing a line of disposable protective apparel and infection control, and building supply products in the United States and internationally. The company operates through two segments, Building Supply and Disposable Protective Apparel. The Building Supply segment offers construction weatherization products, such as house wrap, synthetic roof underlayment, and other woven materials. The Disposable Protective Apparel segment provides shoecovers, bouffant caps, gowns, coveralls, lab coats, hoods, and frocks, as well as face masks and face shields. The company provides its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; pharmaceutical markets; and building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada. Today looks like a solid break-out in a down market. Alpha Pro is part of a $15 Billion dollar industry. With N95 masks in high demand, I think there's only one way this stock can go, UP... On 5/6/2020, the company reported earnings of $0.39 up from $0.09. Revenue spiked with 47.5% sales growth. On 5/6/2020, The company announced it was debt free. Not many companies can say they're debt free. 52-Week high is around $41.00 Last earnings report was a blockbuster! The company blew past Wall Street estimates and I think they'll continue blowing past estimates into the future. Indicators are Bullish. Daily Chart looks great. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
AMEX:APTLong
by HotCharts
$QD can rise in the next daysContextual immersion trading strategy idea. Qudian Inc. provides online small consumer credit products in the People's Republic of China. The demand for shares of the company still looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $1,89; stop-loss — $1,79. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NYSE:QDLong
by KozakHlib
COVID-19 Play - Closed Over $5.00 - July is Here!On May 15, 2020, Sorrento had this to say about the COVID-19 vaccine they are working on... “We’re actually so impressed with the data,” Ji said. “One of the antibodies is so powerful that at a very low concentration it is able to 100% completely prevent infection or inhibit the infection. In our studies, not even one virus escaped from the antibody.” "Phase 1 trial could start within 1st few days of July" - (It mentions this date in the article) "We anticipate having enough material to start Phase 1 trial in patients in the ICU within two (2) months." - (The article I listed was published in May.) Ji was talking about the COVID-19 vaccine they have been working on with Mount Sinai Health System & the University of Texas Medical Branch which has access to the live virus. Anyone thinking this is not the real deal, you might want to think again. Moderna's stock is sitting at $63.04 (After Hours) - What does Moderna have that Sorrento doesn't have? In the article listed herein, Sorrento said "within 2 months..." We are within those two (2) months now. (End of June or July) Link to article: www.biospace.com Today, SRNE broke out above $5.00 On the daily chart, as of today, the Volume spiked, and the MACD, RSI, Stochastic & Accumulation are all Bullish or trending up Bullish. Is news forthcoming? After watching what the stock price of Moderna did and looking at Sorrento trading at $5.12, to me, the reward far outweighs any risk. Also, I believe Sorrento is waiting for an Emergency Use Label on their COVID-19 test that can give you a positive or negative within 8 minutes. Does Moderna have a test? I don't think so. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
SLong
by HotCharts
3
$SY can rise in the next daysContextual immersion trading strategy idea. So-Young International Inc. operates an online platform for medical aesthetics and consumption healthcare services focusing on discretionary medical treatments. The demand for shares of the company still looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $11,31; stop-loss — $10,76. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:SYLong
by KozakHlib
FCC Approved Contactless Temperature Scanner - Options ActivityJune 8, 2020 Remark Holdings (MARK) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. Remark offers products that will help in the crisis and the company owns a stake in Sharecare, the medical startup co-founded by celebrity doctor Mehmet Oz and backed by Oprah Winfrey and Sony (NYSE:SNE). Remark’s innovative products include thermal imaging and scanning solutions that are already in use in Nevada. This artificial intelligence-driven tech can “scan high traffic areas to detect individuals with higher than acceptable skin temperature,” the Wall Street Journal reports. LAS VEGAS, May 27, 2020 /PRNewswire/ -- Remark Holdings, Inc. (NASDAQ: MARK), a diversified global technology company with leading artificial intelligence ("AI") solutions and digital media properties, today announced the launch of a new website, RemarkThermal.com. "Interest in our thermal imaging and scanning solutions is robust across many industries and we believe that enthusiasm warrants a dedicated site for information about our novel solutions," stated Kai-Shing Tao, Chairman and Chief Executive Officer of Remark Holdings, Inc. "What differentiates Remark's thermal cameras are its capabilities beyond thermal temperature scanning. Our proprietary AI software enables monitoring various tasks including people counting, PPE enforcement such as mask wearing, social distancing compliance, contactless access to doors and gates, attendance management, touchless employee check in, object counts, behavior detection, intelligent surveillance and theft control." Remark's Thermal Imaging is used to scan high traffic areas to detect individuals with higher than acceptable skin temperature and track the subject for secondary screening. Each of the Thermal Imaging products is customizable and can operate as a standalone or integrated into centralized control systems, specific to the needs of the customer. Real-time video and audible alerts from individual systems can be sent to a centralized system or monitored live. Systems can be mounted on walls, tripods, or ceilings to scan wider areas. For additional information, please refer to: www.RemarkThermal.com. Options are active. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
MLong
by HotCharts
6
$BZUN can rise in the next daysContextual immersion trading strategy idea. Baozun Inc. provides brand e-commerce service to brand partners in the People's Republic of China. The share price rose after good earnings. I see some preconditions the share price will continue growing. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $37,76; stop-loss — $37,50. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:BZUNLong
by KozakHlib
$SXTC can rise in the next daysContextual immersion trading strategy idea. China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. The demand for shares of the company still looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $0,64; stop-loss — $0,53. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:SXTCLong
by KozakHlib
1
Bullish Charts - Golden CrossBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts. Daily Chart - Golden Cross Stochastic is moving up, Bullish RSI is crossing center line, Bullish Volume just went green on the daily I think the stock is getting ready to move higher. I also think, BSX is one of the cheapest medical device companies in the industry. Long
NYSE:BSXLong
by HotCharts
CNHI Teams with Nikola - 25 Million Share Stake, NEWS There seems to be a disconnect between Nikola, Its Strategic Partners & It's Investors CNHI owns over 25 million shares of Nikola, more than Worthington Industries. (WOR) CNHI has over $4 Billion in cash on hand, more than Worthington Industries. (WOR) CNHI's stake in Nikola is worth over $1.5 Billion dollars or 7.11%, more than Worthington Industries has. CNHI has a market cap of around 10 Billion while Worthington only has a market cap of around 2 Billion. CNHI stock price: $7.08, Worthington Ind. stock price: $35.65 - There's a huge disconnect here. CNHI owns IVECO, one of its subsidiaries working with Nikola on its electric trucks and charging stations. CNHI was part of the spinoff / merger with Nikola, this is how Nikola was started. When you search the news on CNH, IVECO & Nikola, you will see more recent releases including the build-out of a charging network for Nikola vehicles. IVECO is building this for Nikola. Not only are investors buying the wrong stock, as in Worthington Ind.(WOR), in my opinion, the price of CNHI at current levels is an early Christmas Gift. I feel at minimum, CNHI should be trading upwards of $20.00 a share just because of the 25+ million share stake in Nikola, and this is aside from the partnership they have with Nikola through IVECO. 2 News Release Listed Below - (There are more recent news releases) __________________________________________________ RELEASE 1 __________________________________________________ A promising cooperation from the Capital Markets Day CNH Industrial’s Capital Markets Day brought Nikola’s technological innovation to the new Iveco and Fpt Industrial spin-off. CNH Industrial, in fact, announced its intention to enter into a strategic partnership with the company based in Phoenix to accelerate industry transformation towards emission neutrality of Class 8/Heavy-Duty Trucks in North America and Europe through the adoption of fuel-cell technology. The words of Nikola and CNH Trevor Milton, Chief Executive Officer, Nikola Corporation, said: «Nikola has the technology but needs a partner with a European network to achieve it in a timely manner. By bringing CNH Industrial on board, we now have access to manufacturing know-how, purchasing power, validated truck parts, plant engineering and much more». Gerrit Marx, President Commercial and Specialty Vehicles, CNH Industrial, added: «While today LNG delivers significantly lower well-to-wheel emissions, in the medium to long-term, fuel-cell and BEV technologies will deliver the ultimate goal of zero-emission trucking. With our LNG technology we have proven to be European disruptors, taking the lead in industry transformations including fuel supply and lifecycle ownership». __________________________________________________ RELEASE 2 __________________________________________________ Today’s announcement of Nikola Corporation’s intended listing on the NASDAQ Exchange, New York, U.S.A. later this year, through its merger with VectoIQ, is fully supported by CNH Industrial N.V. (NYSE:CNHI / MI:CNHI). “This is exciting news and another key milestone for our joint project to deliver zero emission Heavy-Duty Trucks and hydrogen infrastructure through a unique business model. Nikola’s NASDAQ listing gives further impetus to the ambitious targets we have set ourselves, to be at the forefront of scalable clean technology investments transforming our businesses and environment alike,” said Hubertus Mühlhäuser, Chief Executive Officer, CNH Industrial. CNH Industrial entered into a strategic and exclusive Heavy-Duty Truck partnership with Nikola in September 2019 as the lead Series D investor, with a $250 million stake. IVECO and FPT Industrial, the commercial vehicle and powertrain brands of CNH Industrial, recently announced they will manufacture, through their European Joint Venture with Nikola Motor Company, the Nikola TRE, battery electric (BEV) Heavy-Duty Truck, at IVECO’s Ulm, Germany manufacturing site. Start of production is anticipated within the first half of 2021. “Nikola’s unswerving ambition to comprehensively transform our industry and its environmental footprint represents a great non-cyclical growth path for the business. Listing at NASDAQ, in order to raise funds in today´s market environment, is clear recognition and support of the project’s strategic direction,” said Gerrit Marx, President Commercial and Speciality Vehicles, CNH Industrial. CNH Industrial N.V. (NYSE: CNHI /MI: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and Steyr for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment; Iveco for commercial vehicles; Iveco Bus and Heuliez Bus for buses and coaches; Iveco Astra for quarry and construction vehicles; Magirus for firefighting vehicles; Iveco Defence Vehicles for defence and civil protection; and FPT Industrial for engines and transmissions.
NASDAQ:NKLALong
by HotCharts
2
Bullish Charts - Ready to Explode HigherOrigin Agritech Limited, through its subsidiaries, operates an agricultural biotechnology and an e-commerce platform primarily in the People's Republic of China. The company engages in crop seed breeding and genetic improvement activities. It develops, produces, and distributes hybrid crop seeds, as well as hybrid seed technology. The company also operates an e-commerce platform, which delivers agricultural products comprising agricultural seed products, other agricultural inputs, foods, household products, and other consumer products to farmers through online and mobile ordering. Origin Agritech Limited was founded in 1997 and is headquartered in Beijing, China. From the looks of what I read, SEED is could have approval any day to start growing its biotech corn in China. Looking for a pop soon. Target - $9.00 to $10 Long
NASDAQ:SEEDLong
by HotCharts